DBV reports positive 2-year OLE results for Viaskin Peanut in toddlers; 81.3% reach 1,000 mg eliciting dose

DBV Technologies S.A.

After 24 months, 81.3% of subjects reached eliciting dose >=1,000 mg peanut protein vs 64.2% at 12 months.
55.9% completed the 3,444 mg DBPCFC without meeting stopping criteria, up from 30.7% at 12 months.
No treatment-related anaphylaxis or serious TEAEs in second year; local application site reactions decreased.
Placebo crossover group (12 months VP250) showed 62.7% reaching >=1,000 mg ED; single anaphylaxis event.
Results to be presented at ACAAI Nov 11; investor call/webcast Nov 9 at 5pm ET.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.